United States Department of Veterans Affairs

  CCDOR Investigators

CCDOR logo header
Home Contact CCDOR Contact Webmaster Site Map

   Home  ->  About Us  ->  CCDOR Investigators

Hanna Bloomfield HANNA E. BLOOMFIELD (formerly RUBINS) , MD, MPH
  • Core Investigator, Center for Chronic Disease Outcomes Research
  • Associate Chief of Staff, Research & Development, Minneapolis VA Health Care System
  • Staff Physician, Section of General Internal Medicine, Minneapolis VAMC
  • Professor of Medicine, University of Minnesota School of Medicine
Email  Hanna Bloomfield
  • AB, Harvard College, Cambridge, MA
  • MD, Boston University School of Medicine
  • MPH, Boston University School of Public Health
  • Preventive cardiology
  • Lipids
  • Clinical epidemiology
  • Implementation research
  • Griffin JM, Struve JK, Collins D, Liu A, Nelson DB, Bloomfield HE, Long term clinical trials: How much information do participants retain from the informed consent process? Contemp Clin Trials 2006; 27:441-448.

  • Bloomfield HE, Nelson DB, van Ryn M, Neil BJ, Koets NJ, Basile JN, Samaha FF, Kaul R, Mehta JL, Bouland D. A trial of education, prompts and opinion leaders to improve prescription of lipid modifying therapy by primary care physicians for patients with ischemic heart disease. Qual Saf Health Care 2005; 14: 258-263

  • Rubins HB, Nelson DB, Noorbaloochi S, Nugent S. Effectiveness of lipid lowering medications in outpatients with coronary heart disease in the Department of Veterans Affairs System. Am J Card 2003;92:1177-1182.

  • Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas, FH, Anderson JW for the VA-HIT Study Group. Diabetes, plasma insulin and cardiovascular disease: Subgroup analysis from the VA HDL Intervention Trial. Arch Intern Med 2002;162:2597-2604.

  • Rubins HB, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL-cholesterol: the VA HDL Intervention trial (VA-HIT). Circulation 2001;103:2828-2833.

  • Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB. Relation of events to baseline and on-trial lipids with gemfibrozil in the VA HDL Intervention Trial (VA-HIT), JAMA 2001;285:1585-1591.

  • Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J for the VA-HIT study group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of HDL-cholesterol. N Engl J Med 1999;341:410-418.

To Top

Home  |  Contact CCDOR  |  Contact Webmaster  |  Site Map